Glioblastoma is the most frequent and malignant brain tumor. The vast majority of glioblastomas (approximately 90%) develop rapidly de novo in elderly patients, without clinical or histological evidence of a less malignant precursor lesion (primary glioblastomas). Secondary glioblastomas progress from low-grade diffuse astrocytoma or anaplastic astrocytoma. They manifest in younger patients, have a lesser degree of necrosis, are preferentially located in the frontal lobe and carry a significantly better prognosis. Histologically, primary and secondary glioblastomas are largely indistinguishable, but they differ in their genetic and epigenetic profiles. Decisive genetic signpost of secondary glioblastoma are IDH1 mutations, that are absent in primary glioblastomas and which are associated with a hypermethylation phenotype. IDH1 mutations are the earliest detectable genetic alteration in precursor low-grade diffuse astrocytomas and in oligodendrogliomas, indicating that these tumors are derived from neural precursor cells that differ from those of primary glioblastomas. In this review, we summarize epidemiological, clinical, histopathological, genetic, and expression features of primary and secondary glioblastomas, and the biological consequences of IDH1 mutations.
Introduction

Historical perspective
From a biological and clinical point of view, the secondary glioblastomas developing in astrocytomas must be distinguished from "primary" glioblastomas.
They are probably responsible for most of the glioblastomas of long clinical duration.
H.-J. Scherer (1940) (1) .
was recognized in clinical practice that some glioblastomas developed after resection of low-grade or anaplastic astrocytomas, Scherer's distinction remained conceptual since histopathologically, these subtypes could not reliably be distinguished.
In 1996, we reported evidence that primary and secondary glioblastomas carry distinct genetic alterations (5) . TP53 mutations were found to be uncommon in primary glioblastomas, but occurred with a high incidence in secondary glioblastomas; EGFR overexpression prevailed in primary glioblastomas, but was rare in secondary glioblastomas. Only 1 out of 49 glioblastomas showed TP53 mutation and EGFR overexpression, indicating that these alterations are mutually exclusive events defining two different genetic pathways in the evolution of glioblastoma (5) . Subsequently, many studies provided evidence that primary and secondary glioblastomas develop through distinct genetic pathways (6, 7) . Typical for primary glioblastomas are EGFR amplification, PTEN mutation, and entire loss of chromosome 10 (6-8) . Genetic alterations more common in secondary glioblastomas include TP53 mutations and 19q loss (6, 7, 9) . However, until the identification of IDH1 mutation as a molecular marker of secondary glioblastoma (10) (11) (12) (13) , the patterns of genetic alterations, though different, did not allow an unequivocal separation of the two subtypes.
IDH1 mutations as initiator and lineage marker in gliomagenesis
IDH1/2 mutations in neural tumors IDH1 mutations were first reported by Parsons et al. (14) in 2008 and in this first study the authors already pointed out, that "mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary glioblastomas and were associated with an increase in overall survival'. Subsequent studies showed that these mutations are very frequent in secondary (>80%), but very rare in primary glioblastomas (<5%) (10) (11) (12) (13) . IDH1 mutations as a genetic marker of secondary but not primary glioblastoma closely correspond to the respective clinical diagnosis in 385/407 (95%) of cases (13) . It is now agreed that IDH1 mutation is a definitive diagnostic molecular marker of secondary glioblastomas and more reliable and objective than clinical and/or pathological criteria.
IDH1 mutations are frequent (>80%) in diffuse astrocytoma WHO grade II and anaplastic astrocytoma WHO grade III, the precursor lesions of secondary glioblastomas, as well as in oligodendroglial tumors including oligodendroglioma WHO grade II, anaplastic oligodendroglioma WHO grade III, oligoastrocytoma WHO grade II, and anaplastic oligoastrocytoma WHO grade III (10, 11, 12, 15) . In contrast, IDH1 mutations are very rare or absent in pilocytic astrocytomas, as well as in most other CNS neoplasms, including ependymomas, medulloblastomas, and meningiomas (10, 11, 12, 15) . IDH2 mutations are less frequent and prevail in anaplastic oligodendrogliomas (~5%) and oligoastrocytomas (~6%) (12) .
Research. All IDH1 mutations reported are located at the first or second base of codon 132 (10, 11, 14) . Most frequent is R132H (CGT->CAT), observed in 83-91% of IDH1 mutations in astrocytic and oligodendroglial gliomas (10) (11) (12) . Other mutations are rare, including R132C (CGT->TGT) (3.6-4.6%) (10-12), R132G (0.6-3.8%) (10) (11) (12) , R132S (0.8-2.5%) (10) (11) (12) , and R132L (0.5-4.4%) (10, 12) . IDH2 mutations are located at codon 172 (12), with R172K being most frequent.
IDH1/2 mutations in non-neural tumors IDH1/2 mutations are absent or very rare in most tumors at other organ sites, including bladder, breast, stomach, colorectum, lung, liver, ovary and prostate (12, 15) . Exceptions are central chondrosarcomas (~55%) (16) , intrahepatic cholangio-carcinomas (23%) (17) , acute myeloid leukemia (AML; 15-20%) (18) (19) (20) (21) (22) (23) , angioimmunoblastic T-cell lymphoma (AITL; ~20%) (24) malignant melanoma (~10%) (25) , and anaplastic thyroid cancer (~10%) (26) . This suggests that IDH1/2 mutations may confer a growth advantage in specific cell lineages at defined stages of development and differentiation.
Are there primary glioblastomas with IDH1 mutations?
In a population-based study, only 14 of 407 glioblastomas clinically diagnosed as primary (3.4%) carried an IDH1 mutation (13) . These patients were 10 years younger and their genetic profiles were similar to those of secondary glioblastomas, including frequent TP53 mutations and absence of EGFR amplification (13) . Similarly, several hospital-based studies showed that primary glioblastomas with IDH1 mutations were 13-27 years younger than those without IDH1 mutations (10, 12, 27, 28) . Toedt et al. (27) showed that primary glioblastomas with IDH1 mutations have gene expression profiles similar to those of IDH1 mutated secondary glioblastomas. Glioblastomas with IDH1 mutations clinically diagnosed as primary may have rapidly progressed from precursor lesions that escaped clinical diagnosis and are likely to have been misclassified as primary glioblastoma.
Are there secondary glioblastomas that do not have IDH1 mutations?
Secondary glioblastomas lacking IDH1 mutations have infrequent TP53 mutations, and patients have a shorter clinical history (13) . Furthermore, most secondary glioblastomas lacking IDH1 mutations (7/8) had developed through progression from an anaplastic glioma (WHO grade III), whereas the majority of secondary glioblastomas with IDH1 mutations had progressed from a WHO grade II glioma (13) . The possibility therefore exists that some tumors diagnosed as anaplastic astrocytoma were actually primary glioblastomas that were misdiagnosed due to a sampling error. In the absence of diagnostic hallmarks, i.e. necrosis and/or microvascular proliferation pathologists hesitate to make a diagnosis of glioblastoma even if MRI imaging suggests this.
Research. (11, (29) (30) (31) (32) (33) . IDH1/2 mutations is likely to occur before TP53 mutation or 1p/19q loss, since low-grade diffuse gliomas carrying only IDH1/2 mutations are more frequent (17%) than those carrying only a TP53 mutation (2%) or those showing only 1p/19q loss (3%) (33) . Furthermore, the analysis of multiple biopsies from the same patient revealed that there was no cases in which an IDH1 mutation occurred after the acquisition of a TP53 mutation or loss of 1p/19q (11, 33) .
Acquisition of 1p/19q loss in cells with IDH1/2 mutations may be the driving force towards oligodendroglial differentiation in low-grade diffuse glioma (11, 31, 33) . It has been shown that tumors with the typical histological signature of oligodendroglioma (e.g. Only 7% of WHO grade II diffuse gliomas had none of these genetic alterations (i.e.
IDH1/2 mutations, TP53 mutations, 1p/19q loss) and were termed "triple negative" (33) .
These cases are still poorly understood; a minor fraction shows loss of cell cycle control regulated by the RB1 pathway (38) . The possibility cannot be excluded that they are derived from a different precursor cell population. exception, all contained the R132C (CGT>TGT) mutation (41) , which in sporadic astrocytic tumours amounts to less than 5% of all IDH1 mutations (10) (11) (12) . This remarkably selective occurrence suggests a preference for R132C mutations in neural precursor cells that already carry a germline TP53 mutation.
IDH1 mutations in gliomas associated with the Li-Fraumeni syndrome
Biological consequences of IDH mutations
The mechanisms by which IDH1 mutations contribute to the development and malignant progression of astrocytic and oligodendroglial tumors are still not fully understood.
Conditional IDH1 (R132H) knock-in mice with expression in all hematopoietic cells or cells of the myeloid lineage caused an increased number of early hematopoietic progenitors with splenomegaly, anemia and extramedullary hematopoiesis (42) , while brain-specific IDH1 (R132H) conditional knock-in mice exhibited hemorrhage and perinatal lethality (43) . Like EGFR amplification in primary glioblastomas, IDH1 mutations in secondary glioblastomas are typically lost during culture in vitro (44) . This is enigmatic, since selective suppression of endogenous mutant IDH1 expression in a fibrosarcoma cell line with a native IDH1R132C heterozygous mutation, significantly inhibits cell proliferation (45) . Only recently, using a neurosphere culture method, it has been possible to establish a brain tumor stem cell line from an IDH1-mutant anaplastic oligoastrocytoma with an endogenous IDH1 mutation and detectable production of 2-hydroxyglutarate (2HG) (46) . This may suggest that IDH1-mutant glioma cells have stem-cell-like features that confer a growth advantage under neurosphere culture conditions. Alternatively, there may be intra-tumoral heterogeneity of IDH1 mutations, and neoplastic cells lacking IDH1 mutations are positively selected during culture.
Impaired enzymatic activity and accumulation of 2-hydroxyglutarate
The IDH1 gene encodes isocitrate dehydrogenase 1, an enzyme participating in the citric acid (Krebs) cycle (47, 48) , the metabolic pathway used by aerobic organisms to generate usable energy (49) . IDH1/2 mutations reduce the wild-type activity of the enzyme, i.e. the conversion of isocitrate to α-ketoglutarate (α-KG), and increase levels of hypoxia inducible factor-1α (HIF-1α), a transcription factor, and its targets (e.g. GLUT1, VEGF and PGK1) (50) . Importantly, IDH1/2 mutations are gain-of-function mutations that also produce the oncometabolite 2HG from α-KG (51,52). The production of 2HG is a function shared by all the commonly occurring IDH1/2 mutants analyzed (51-53). Malignant IDH1 mut gliomas contain an increased (up to 100-fold) concentration of 2HG (51) . Cells from brain-specific IDH1 (R132H) conditional knock-in mice also show high levels of 2HG that are associated with inhibited prolyl-hydroxylation of HIF-1α and upregulation of its target genes (43) . 2HG also blocks prolyl-hydroxylation of collagen, causing a defect in collagen protein Incidence of secondary glioblastomas Until the discovery of IDH1 mutations as a molecular marker, the distinction between primary and secondary glioblastomas was based on clinical observations. Tumors were considered primary if the diagnosis of glioblastoma was made at the first biopsy, without radiological or histological evidence of a pre-existing, less malignant precursor lesion. The diagnosis of secondary glioblastoma required neuro-imaging and/or histological evidence of a preceding low-grade or anaplastic astrocytoma (6,7).
In developed countries, the annual incidence of glioblastomas is usually in the range of 3-4 cases per 100'000 persons per year (7, (63) (64) (65) . In a population-based study in Switzerland, using clinical criteria and histopathological evidence, only 5% of all glioblastomas diagnosed were secondary (7, 63) . Similarly, a study by the University of Alabama showed that 19 of 392 (5%) cases of glioblastoma had a histologically proven prior low-grade glioma (66) . When IDH1 mutations are used as a genetic marker, secondary glioblastomas accounted for 9% of all glioblastomas at the population level (13) and for 6-13% in hospital-based studies (10,12,67,68).
The combined incidence rates of low-grade and anaplastic astrocytomas are approximately twice as high as that of clinically diagnosed secondary glioblastoma or IDH1 mut glioblastoma (30, 64, 69) . This may be explained at least in part by the fact that some patients with low-grade or anaplastic astrocytoma succumb to the disease before progression to glioblastoma occurs. Further, cases with rapid progression from low-grade or anaplastic astrocytoma may be misclassified as primary glioblastoma.
Age and sex distribution
There is a striking difference in the age distribution of patients with primary and secondary glioblastoma. At a population level, the mean age of glioblastoma patients clinically diagnosed as primary was 62 years, while secondary glioblastomas developed in younger patients (mean, 45 years) (7, 63) . Similarly, the mean ages of patients with or without IDH1 mutations were 61 and 48 years, respectively ( Glioblastomas predominantly affect males, with a population-based M/F ratio ranging from 1.28 (7) to 1.32 (64, 65) . In contrast, diffuse astrocytomas (WHO grade II) have a less pronounced male predominance, with M/F ratios of approximately 1.17 (29, 65) . Since secondary glioblastomas typically develop from diffuse astrocytomas, one would expect that they have a similar gender ratio. This is indeed the case. In a population-based study, tendency towards a lower M/F ratio of patients with secondary glioblastomas (5, (71) (72) (73) (74) . In a recent multi-center study, 49 of 618 glioblastomas (7.9%) carried an IDH1 mutation and had an M/F ratio of 0.96, in contrast to a ratio of 1.63 for non-mutated (primary) glioblastomas (68) .
Clinical history
At a population level, the majority of patients with primary glioblastoma (68%) had a clinical history of less than 3 months (6). The mean duration of the clinical history of patients with primary and secondary glioblastoma was 6.3 and 16.8 months, respectively (7, 63) . (77) showed that oligodendrogliomas with 1p/19q loss were located predominantly in the frontal lobe. These observations suggest that oligodendrogliomas, astrocytomas, and secondary glioblastomas derived thereof originate from precursor cells located in or migrating to, the frontal lobe. 
Extent of necrosis
Histopathologically, large areas of ischemic and/or pseudopalisading necrosis are more frequent in primary (89%) than secondary glioblastomas (63%, P=0.0014) (80) and glioblastomas without IDH1 mutations (90% vs. 50%; P<0.0001) (13) ( Table 1 ). This was confirmed in clinical MRI studies showing that necrosis was less frequent in IDH1 mut glioblastomas while exhibiting more frequent non-enhancing tumor components, larger size at diagnosis, lesser extent of edema, and increased prevalence of cystic and diffuse components (68) .
Histological features
According to the 2007 WHO classification, histological criteria for the diagnosis of glioblastoma include nuclear atypia, cellular pleomorphism, mitotic activity, vascular thrombosis, microvascular proliferation, and necrosis (29) . Glioblastomas may show significant intertumoral and intratumoral heterogeneity, both histologically and genetically (80) (81) (82) and this may also apply to glioma initiating cells (82, 83) . This heterogeneity reflects genomic instability and occasionally, focal new clones arising as a result of additional genetic alterations can be seen histologically (84, 85) . Areas with oligodendroglioma-like components are significantly more frequent in secondary than primary glioblastomas (42% vs. 18%, P=0.0138) (80) and, accordingly, more frequent in IDH1 mut glioblastomas than in IDH1 wt glioblastomas (54% vs. 20%; P<0.0001) (13) ( Table 1 ). An increase in the fraction of tumor cells with oligodendroglial morphology in IDH1 mut glioblastomas was also reported in a large study of 618 cases (68). This is not surprising since secondary glioblastomas assumedly share IDH1 mut precursor cells with oligodendrogliomas ( Fig. 1) .
Clinical outcome
In a population-based study, the median overall survival of clinically diagnosed secondary glioblastoma was 7.8 months, significantly longer than the survival of patients with primary glioblastoma (4.7 months; P=0.003) (7) . Similarly, the analysis of glioblastoma patients who were treated with surgery and radiotherapy showed that the mean overall survival time There is also evidence that cancer stem cells in primary and secondary glioblastomas may also be different. In one study, the relative content of CD133+ cells was significantly higher in primary than in secondary glioblastomas, and CD133+ expression was associated with neurosphere formation only in primary, but not secondary glioblastomas (86) .
Phenotype / genotype correlations Despite differences in clinical history and genetic, epigenetic and expression profiles, primary and secondary glioblastomas are histologically largely indistinguishable, except that extensive necrosis is more frequent in primary glioblastomas and oligodendroglioma components are more frequent in secondary glioblastomas (80) ( Table 1 ). This similarity may be attributable to genetic alterations that are common to both primary and secondary glioblastomas.
The most frequent genetic alteration shared by both primary and secondary glioblastomas is LOH at 10q (up to 60% of cases) (6) (7) (8) (87) (88) (89) , the most commonly deleted region being 10q25-qter, distal to D10S1683 (8) . Since mutations of the PTEN gene located at 10q23.3 prevail in primary glioblastomas (~25%), but are rare in secondary glioblastomas (<5%) (6, 7, 90) , loss of function of gene(s) other than PTEN is likely to be responsible for the common malignant phenotype. Circumscribed glioblastoma foci in lowgrade diffuse astrocytoma or anaplastic astrocytoma show additional deletions at 10q25-qter, distal to D10S597, including the DMBT1 and FGFR2 loci (84) . This suggests that the 
